Modality
mAb
MOA
PARPi
Target
TNFα
Pathway
Neuroinflam
Parkinson'sPV
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Jun 2027
Phase 2Current
NCT08261113
2,186 pts·Parkinson's
2024-10→2027-06·Terminated
NCT07363320
2,382 pts·Parkinson's
2020-10→TBD·Terminated
4,568 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-151.2y awayPh3 Readout· Parkinson's
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-06-15 · 1.2y away
Parkinson's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08261113 | Phase 2/3 | Parkinson's | Terminated | 2186 | MRD |
| NCT07363320 | Phase 2/3 | Parkinson's | Terminated | 2382 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Cevifotisoran | Neurocrine | Approved | CD47 |